Category: Insights

Contribution of NIH funding to new drug approvals 2010–2016

This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
The po…


Understanding the Barriers to US Biosimilars

Without a strong biosimilars market, costs for biologics in the US continue trending upward.  The world of drug patents for biosimilars in the United States is far more complex than…
The post Understanding the Barriers to US Biosimilars appeared …


Formulary Decisions: Exploring the Ethics of Drug Approval

Formularies come into effect at the hospital level and the individual insurer level When developed and managed with due care and consideration, drug formularies can be a good tool for…
The post Formulary Decisions: Exploring the Ethics of Drug Ap…


Top 6 issues facing the biotechnology industry

For the last century, drug development consisted of tiny-molecule treatments focused at mass audience. It worked for some patients while it didn’t for the rest. In some cases, we knew…
The post Top 6 issues facing the biotechnology industry appea…


Tracking 20 Years of Compound-to-Target Output from Literature and Patents

This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
The post Tracking 20 Years…


The Importance of Pharmaceutical Competitor Analysis

The US pharmaceutical industry is heavily competitive, with nine out of the top ten pharmaceutical companies based in the US. In recent years though, the market has become even more competitive…
The post The Importance of Pharmaceutical Competito…


Celgene vs. Dr. Reddy’s Revlimid patent infringement case depends on polymorph stability; lack thereof may favor Celgene position – experts

This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of GlobalData. Polymorph differences support noninfringement argument Trace solvate amount could destabalise…
The post C…


Making Medicines Affordable: A National Imperative

Consumer access to effective and affordable medicines is an imperative for public health, social equity, and economic development, but this need is not being served adequately by the biopharmaceutical sector,…
The post Making Medicines Affordable…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: